Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1897–1920 of 2,206 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: All Clear all

Conditions: Neoplasms
Interventions: Smoked Marijuana; Drug
Lead sponsor: Center for Medicinal Cannabis Research; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pediatric ALL, Sepsis
Interventions: Pediatric eCART; Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: Up to 17 Years
Enrollment: 30,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Burns, Pediatric ALL
Interventions: Face-to-face burn care, Telemedicine enhanced burn care; Procedure
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 0 Years to 80 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Knee Osteoarthritis
Interventions: Strength training, Aerobic conditioning, Delayed exercise; Behavioral
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 50 Years and older
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Childhood Cancer
Interventions: JUMP; Behavioral
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 6 Years to 17 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Non-Hodgkins Lymphoma, Sarcoma, Neuroblastoma
Interventions: Food Safety Guidelines, Neutropenic Diet; Other
Lead sponsor: Indiana University; Other
Eligibility: 1 Year to 30 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 6
States / cities: San Diego, California • Indianapolis, Indiana • Brooklyn, New York + 2 more

Conditions: Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Mixed Phenotype Acute Leukemia
Interventions: Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration and Biopsy, Ipilimumab, Nivolumab; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 7
States / cities: New Haven, Connecticut • Lexington, Kentucky • Baltimore, Maryland + 4 more

Conditions: Cytokine Release Syndrome, ICANS, Lymphoma, Non-Hodgkin, Multiple Myeloma, Acute Lymphoblastic Leukemia
Interventions: Siltuximab; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: B Precursor Type Acute Leukemia
Interventions: Dietary Intervention, Activity and Exercise Intervention; Behavioral
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 10 Years to 21 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: ziv-aflibercept; Biological
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 25 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: L-756423, Indinavir sulfate, Lamivudine, Stavudine; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 16
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Fort Myers, Florida + 9 more

Conditions: Hematological Malignancies
Interventions: Tacrolimus and Thymoglobulin; Drug
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: aldesleukin, recombinant interferon alfa; Biological
Lead sponsor: Hoag Memorial Hospital Presbyterian; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 1999
U.S. locations: 5
States / cities: Newport Beach, California • Bloomington, Indiana • Indianapolis, Indiana + 2 more

Conditions: Leukemia
Interventions: Cordycepin, Deoxycoformycin; Drug
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2001
U.S. locations: 13
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Boston, Massachusetts + 6 more

Conditions: Hematologic Malignancies, Inborn Errors of Metabolism Disorders, Immune Deficiencies
Interventions: CliniMACS CD34 Reagent System; Biological
Lead sponsor: Joanne Kurtzberg, MD; Other
Eligibility: Up to 65 Years
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Acute Pain, Pediatric ALL, Procedural Pain, Burns
Interventions: VR-PAT; Other
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 6 Years to 17 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hematologic Malignancy, Myelodysplastic Syndrome (MDS), Aplastic Anemia
Interventions: haplo/cord transplant; Biological
Lead sponsor: Joanne Kurtzberg, MD; Other
Eligibility: Up to 55 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: AML, Adult Recurrent, ALL, Recurrent, Adult, MDS
Interventions: SOC + BSB-1001 Dose Escalation Cohort, SOC+BSB-1001 Expansion Dose; Drug
Lead sponsor: BlueSphere Bio, Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 6
States / cities: Duarte, California • Tampa, Florida • Ann Arbor, Michigan + 3 more

Conditions: Leukaemia
Interventions: SAR440234; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 16 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, Myelodysplastic Syndrome
Interventions: Cyclophosphamide, Fludarabine, Fludarabine Phosphate, Granulocyte Colony-Stimulating Factor, Hematopoietic Cell Transplantation, Intensity-Modulated Radiation Therapy, Mycophenolate Mofetil, Tacrolimus; Drug · Biological · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 12 Years to 60 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myeloproliferative Neoplasms
Interventions: anti-thymocyte globulin, G-CSF, busulfan, fludarabine phosphate, methotrexate, mycophenolate mofetil, tacrolimus, allogeneic cell transplantation, allopurinol; Biological · Drug · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: Up to 69 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 12
States / cities: La Jolla, California • Lewes, Delaware • Newark, Delaware + 9 more

Conditions: Acute Lymphoblastic Leukemia
Interventions: RAPAMYCIN; Drug
Lead sponsor: University of Utah; Other
Eligibility: Up to 21 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Leukemia, Acute, AML, Adult, ALL, Adult, Myelodysplastic Syndromes
Interventions: Palliative Care Visits; Other
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Leukemia, Lymphoma, Myelodysplastic Syndromes
Interventions: filgrastim, cyclophosphamide, cyclosporine, cytarabine, methotrexate, methylprednisolone, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: Up to 55 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2005
U.S. locations: 13
States / cities: Stanford, California • Iowa City, Iowa • Lexington, Kentucky + 10 more

Search by objective public record fields.

Marijuana for Cancer Pain

Evaluation of Pediatric eCART Implementation

Telemedicine Optimized Burn Intervention

Exercise and Physical Fitness for Persons With Knee Osteoarthritis

Examining a Training Program for for Acute Lymphoblastic Leukemia Childhood Cancer Survivors

The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients

Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

Improving Diet and Exercise in Acute Lymphoblastic Leukemia (IDEAL Weight in ALL)

VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma

A Study to Compare the Safety and Effectiveness of Indinavir Combined With Stavudine and Lamivudine

Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT

Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer

Chemotherapy With Cordycepin Plus Pentostatin in Treating Patients With Refractory Acute Lymphocytic or Chronic Myelogenous Leukemia

Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants

VR-PAT and fNIRS to Identify CNS Biomarkers of Pain

Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies

BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS

First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome

Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer

Rapamycin for Immunosuppression and B Cell Modulation Post Stem Cell Transplant for Acute Lymphoblastic Leukemia (ALL)

Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS

Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma